ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer

Recently, a nonsense alteration Trp149Stop in the ARLTS1 gene was found more frequently in familial cancer cases versus sporadic cancer patients and healthy controls. Here, the role of Trp149Stop or any other ARLTS1 germline variant was evaluated on breast, prostate, and colorectal cancer risk. The whole gene was screened for germline alterations in 855 familial cancer patients. The five observed variants were further screened in 1169 non-familial cancer patients as well as in 809 healthy population controls. The Trp149Stop was found at low frequencies (0.5–1.2%) in all patient subgroups versus 1.6% in controls, and the mutant allele did not co-segregate with disease status in families with multiple affected individuals. The CC genotype in the Cys148Arg variant was slightly more common among both familial and sporadic breast (odds ratio (OR), 1.48; 95% confidence interval (CI), 1.16–1.87; P=0.001) and prostate cancer patients (OR, 1.50; 95% CI, 1.13–1.99; P=0.005) when compared to controls. A novel ARLTS1 variant Gly65Val was found at higher frequency among familial prostate cancer patients (8 of 164, 4.9%) than in controls (13 of 809, 1.6%; OR, 3.14; 95% CI, 1.28–7.70, P=0.016). However, after adjusting for multiple testing, none of these results were still significant. No association was found with any of the variants and colorectal cancer risk. Our results suggest that Trp149Stop is not a predisposition allele in breast, prostate, or colorectal cancer in the Finnish population, and, while the Gly65Val variant may increase familial prostate cancer risk and the Cys148Arg change may affect both breast and prostate cancer risk, the evidence is not strong in these data.

[1]  Louis Renault,et al.  Arf, Arl, Arp and Sar proteins: a family of GTP‐binding proteins with a structural device for ‘front–back’ communication , 2002, EMBO reports.

[2]  Á. Carracedo,et al.  Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancer. , 2007, Carcinogenesis.

[3]  J. Schleutker,et al.  Genetic changes in familial prostate cancer by comparative genomic hybridization , 2001, The Prostate.

[4]  W James Gauderman,et al.  Sample size requirements for matched case‐control studies of gene–environment interaction , 2002, Statistics in medicine.

[5]  R. Houlston,et al.  Familial cancer associated with a polymorphism in ARLTS1. , 2006, The New England journal of medicine.

[6]  K Holli,et al.  Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. , 2000, Journal of the National Cancer Institute.

[7]  J. Schleutker,et al.  Germ-line alterations in MSR1 gene and prostate cancer risk. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[9]  B J Williams,et al.  Comparative genomic hybridization. , 1996, Methods in molecular medicine.

[10]  H. Nevanlinna,et al.  Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? , 2000, European journal of cancer.

[11]  B. Burwinkel,et al.  Familial cancer and ARLTS1. , 2005, The New England journal of medicine.

[12]  Zhaohui S. Qin,et al.  Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. , 2002, American journal of human genetics.

[13]  H. Nevanlinna,et al.  A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families , 2001, British Journal of Cancer.

[14]  O. Cussenot,et al.  Extensive analysis of the 13q14 region in human prostate tumors: DNA analysis and quantitative expression of genes lying in the interval of deletion , 2003, The Prostate.

[15]  J. Schleutker,et al.  CHEK2 variants associate with hereditary prostate cancer , 2003, British Journal of Cancer.

[16]  K. Hemminki,et al.  ARLTS1 variants and melanoma risk , 2006, International journal of cancer.

[17]  A. Whittemore,et al.  A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. , 2005, American journal of human genetics.

[18]  P. Bugert,et al.  Association of the ARLTS1 Cys148Arg variant with familial breast cancer risk , 2006, International journal of cancer.

[19]  L. Aaltonen,et al.  Population-based molecular detection of hereditary nonpolyposis colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Aaltonen,et al.  CHEK2 I157T associates with familial and sporadic colorectal cancer , 2005, Journal of Medical Genetics.

[21]  E. Frank.  Book Review Women's Mental Health: A Life-Cycle Approach Edited by Sarah E. Romans and Mary V. Seeman. 414 pp. Philadelphia, Lippincott Williams & Wilkins, 2005. $59.95. 0-7817-5129-2 , 2005 .

[22]  H. Brenner,et al.  ARLTS1 variants and risk of colorectal cancer. , 2006, Cancer letters.

[23]  R. Houlston,et al.  Relationship between ARLTS1 polymorphisms and risk of chronic lymphocytic leukemia. , 2006, Leukemia research.

[24]  L. Aaltonen,et al.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.

[25]  W. Holland.  Screening for Disease , 1969, Nature.

[26]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[27]  D. Iliopoulos,et al.  Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. , 2006, Cancer research.

[28]  K. Tsurugi,et al.  An ARL1 mutation affected autophagic cell death in yeast, causing a defect in central vacuole formation , 2002, Cell Death and Differentiation.

[29]  O. Cussenot,et al.  High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy. , 2005, Urologic oncology.

[30]  E. Gillanders,et al.  Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Päivi Heikkilä,et al.  CHEK2 variant I157T may be associated with increased breast cancer risk , 2004, International journal of cancer.